Lipoprotein(a) reduction by canakinumab, a monoclonal antibody targeting interleukin-1Beta, explains a significant portion of the favorable outcomes of the cantos trial

2021 ◽  
Vol 331 ◽  
pp. e36
Author(s):  
C.G. Schrock
2021 ◽  
pp. 1-5
Author(s):  
Chloe J. Walker ◽  
Kelly E. Flanagan ◽  
James T. Pathoulas ◽  
Isabel Pupo Wiss ◽  
Maryanne M. Senna

<b><i>Introduction:</i></b> Tocilizumab (TCZ), a recombinant humanized antihuman monoclonal antibody targeting interleukin-6 (IL-6) signaling, is often utilized in the management of autoimmune disease. Few reports have demonstrated hair growth changes in patients on TCZ. <b><i>Case Presentation:</i></b> Herein, we review the literature and report a 21-year-old woman with progressive alopecia areata (AA) presenting with AA improvement while on TCZ for concomitant posterior uveitis. <b><i>Discussion:</i></b> Our case demonstrates the potential ability of TCZ to disrupt IL-6 signaling involved in AA, leading to hair loss and regrowth.


Circulation ◽  
2013 ◽  
Vol 128 (9) ◽  
pp. 962-969 ◽  
Author(s):  
Nihar R. Desai ◽  
Payal Kohli ◽  
Robert P. Giugliano ◽  
Michelle L. O’Donoghue ◽  
Ransi Somaratne ◽  
...  

2011 ◽  
Vol 162 (8) ◽  
pp. 1855-1870 ◽  
Author(s):  
EG Stefanich ◽  
DM Danilenko ◽  
H Wang ◽  
S O'Byrne ◽  
R Erickson ◽  
...  

Author(s):  
Srinu Tumpara ◽  
Elena Korenbaum ◽  
Tobias Welte ◽  
Beatriz Martinez Delgado ◽  
Sabina Janciauskiene

Sign in / Sign up

Export Citation Format

Share Document